Comparative Pharmacology
Head-to-head clinical analysis: UNIRETIC versus VASERETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNIRETIC versus VASERETIC.
UNIRETIC vs VASERETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Uniretic is a combination of an angiotensin-converting enzyme (ACE) inhibitor (moexipril) and a thiazide diuretic (hydrochlorothiazide). Moexipril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing excretion of sodium and water.
Vaseretic is a combination of enalapril maleate (an angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (a thiazide diuretic). Enalapril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and chloride excretion by inhibiting the Na+-Cl- symporter in the distal convoluted tubule, leading to diuresis and vasodilation.
1-2 tablets (each containing hydrochlorothiazide 25 mg and spironolactone 25 mg) orally once daily. Maximum dose: 4 tablets/day.
One tablet (10 mg enalapril maleate/25 mg hydrochlorothiazide) orally once daily; may increase to 2 tablets daily if needed.
None Documented
None Documented
Terminal elimination half-life 13-17 hours; clinical context: supports once-daily dosing
Enalaprilat: 35–38 hours (terminal). Clinically, effective half-life ~11 hours. Prolonged in renal impairment (CrCl <30 mL/min: up to 60 hours).
Renal: 50-70% unchanged; biliary/fecal: 10-15% as metabolites
Renal: 60% (enalaprilat); biliary/fecal: 33% (enalaprilat). Unchanged enalapril: <5% in urine.
Category C
Category C
ACE Inhibitor and Diuretic
ACE Inhibitor/Diuretic Combination